Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia

American Journal of Psychiatry

Volumn 154, Issue 6, 1997, Pages 782-791

  Zimbroff, Dan L ^a   Kane, John M ^a   Tamminga, Carol A ^a   Daniel, David G ^a   Mack, Randall J ^a   Wozniak, Patricia J ^a   Sebree, Terri B ^a   Wallin, Bruce A ^a   Kashkin, Kenneth B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; SERTINDOLE;

ADULT; AGED; AKATHISIA; AMBLYOPIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SAFETY; EJACULATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM DISEASE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; NAUSEA; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0030913838     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.6.782     Document Type: Article

References (34)

1. Delay J, Deniker P: Trente-huit cas de psychoses traitées par la cure prolongée et continue de 4500 RP [Thirty-eight cases of psychosis treated by chronic treatment with 4500 RP], in Congrès des Médecins Alienistes et Neurologistes de France. Edited by Masson P. Luxembourg, MANF, 1952, pp 497-502
2. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20:140-144
3. Anden NE, Butcher SC, Corrodi H, Fuxe K, Ungerstedt U: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 1970; 11:303-314
4. Snyder SH, Creese I, Burt D: The brain's dopamine receptor: labeling with [3H]dopamine and [3H]haloperidol. Psychopharmacol Commun 1975; 1:663-673
5. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719
6. Creese I, Burt DR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192:481-483
7. Skarsfeldt T, Perregaard J: Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 1990; 182:613-614
8. Chiodo LA, Bunney BS: Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 1985; 5:2539-2544
9. Kane I, Honigfeld G, Singer J, Mehltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
10. Kane JM, McGlashan TH: Treatment of schizophrenia. Lancet 1995; 346:820-825
11. Umbricht DS, Pollack S, Kane JM: Clozapine and weight gain. J Clin Psychiatry 1994; 55(Sept suppl B):157-160
12. Wilson WH, Claussen AM: Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 1995; 55(5):184-188
13. Hyttel J: Sertindole - a new concept in neuroleptic research, in Modern Trends in the Treatment of Schizophrenia: Proceedings of a Symposium. New York, Excerpta Medica, 1991, pp 3-12
14. Skarsfeldt T: Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992; 10:25-33
15. Sanchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, Perregaard J, Skarsfeldt T: Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Development Res 1991; 22:239-250
16. Domeney AM, Arnt J, Costall B, Naylor RJ, Sanchez C, Smith AG: Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Development Res 1994; 31:175-185
17. Casey DE: Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl) 1996; 124:134-140
18. van Kammen D, McEvoy J, Targum S, Kardatzki D, Sebree TB: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996; 124:168-175
19. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
20. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
21. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
22. Andreasen NC: Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39:784-788
23. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 219-222
24. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
25. Barnes TR: A rating scale for drug-induced akathisia. Br J Pharmacol 1989; 154:672-676
26. COSTART: Coding System for Thesaurus of Adverse Reactions Terms, 3rd ed. Rockville, Md, US Department of Health and Human Services, Food and Drug Administration, Center for Drug and Biologies, Division of Drug and Biological Experience, 1989
27. SAS/STAT User's Guide, version 6, 4th ed, vol 1. Cary, NC, SAS Institute, 1989, p 943
28. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol; acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
29. Schultz SC, Bark NM, Zborowski J, Schmitz P, Sebree T, Wallin B: Efficacy and safety of sertindole in two double-blind, placebo-controlled trials for schizophrenic patients, in Institute Proceedings and Syllabus Summary, American Psychiatric Association 47th Institute on Psychiatric Services. Washington, DC, APA, 1995
30. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287-302
31. Sebree T: Efficacy, safety and dose response of three doses of sertindole and three doses of haloperidol, in ACNP Scientific Abstracts 1995. Nashville, Tenn, ACNP, 1995, p 86
32. van Kammen D, Holgate KL, Sebree T, Zborowski J, Schmitz P, Wallin B: Two open-label, long-term safety studies of sertindole. Ibid, p 278
33. Garson A Jr: How to measure the QT interval - what is normal? Am J Cardiol 1993; 72(6):14B-16B
34. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: psychosis and anxiety, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York, McGraw-Hill, 1996, pp 399-130